Early Phase 1 Multiple Sclerosis Trial, Not Yet Recruiting NCT07392528 Sponsor: Tianjin Huanhu Hospital Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Early Phase 1 Multiple Sclerosis Trial, Not Yet Recruiting

NCT07392528
Not Yet Recruiting Early Phase 1

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 years or older.
  • People with a neurological autoimmune disease that has come back or has not responded to treatment, including neuromyelitis optica spectrum disorders (NMOSD), myasthenia gravis (MG), multiple sclerosis (MS), autoimmune encephalitis (AE), or chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
  • Women who could become pregnant and men whose partners could become pregnant must use an approved form of contraception or abstain from sex during the study treatment and for at least 6 months after it ends; women who could become pregnant must have a negative pregnancy test (HCG) within 7 days before joining the study and must not be breastfeeding.
  • People who are willing to take part, sign a consent form, follow the study requirements, and attend follow-up appointments.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have a history of severe allergic reactions to medications or who are known to have a strong tendency toward allergies.
  • People who have been diagnosed with cancer in the past five years, except for certain low-risk conditions such as non-melanoma skin cancer, early-stage tumours with a low chance of returning after full removal, localised prostate cancer that has been treated, certain early-stage cervical conditions, or stable thyroid cancers of specific types (confirm with trial site).
  • People with poor or insufficient heart function.
  • People who test positive for hepatitis B surface antigen or hepatitis B core antibody with detectable hepatitis B virus in the blood; people who test positive for hepatitis C antibody with detectable hepatitis C virus in the blood; people who test positive for HIV; or people who test positive for syphilis.
  • Women who are pregnant or who are planning to become pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 17 August 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Phone: 18622271026

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Early Phase 1
Sponsor
Tianjin Huanhu Hospital
Registry
ClinicalTrials.gov
Start date
1 March 2026
Est. completion
1 June 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The number and severity of dose-limiting toxicity (DLT) events; The total number, incidence, and severity of AEs

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 17 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov